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Abstract
Conversion of somatic cells to pluripotency by defined factors is a long and complex process that
yields embryonic stem cell-like cells that vary in their developmental potential. To improve the
quality of resulting induced pluripotent stem cells (iPSCs), which is important for potential
therapeutic applications, and to address fundamental questions about control of cell identity,
molecular mechanisms of the reprogramming process must be understood. Here we discuss recent
discoveries regarding the role of reprogramming factors in remodeling the genome, including new
insights into the function of c-Myc, and describe the different phases, markers and emerging
models of reprogramming.
Introduction
Resetting the epigenome of a somatic cell to a pluripotent state has been achieved by
somatic cell nuclear transfer (SCNT), cell fusion, and ectopic expression of defined factors
such as Oct4, Sox2, Klf4 and c-Myc (OSKM)1–3. Understanding the molecular mechanisms
underlying somatic cell reprogramming to pluripotency is critical for the creation of high-
quality pluripotent cells and may be useful for therapeutic applications. Moreover, gaining
insight from in vitro reprogramming approaches may yield relevant information for SCNT
or cell fusion-mediated reprogramming and may broaden our understanding of fundamental
questions regarding cell plasticity, cell identity and cell fate decisions4–6.
Reprogramming by SCNT is rapid, is thought to be deterministic and yields embryonic stem
cells (ESCs) from the cloned embryo that are similar to ESCs derived from the fertilized
embryo7,8. However, the investigation of SCNT and cell fusion is difficult because oocytes
and ESCs contain multiple gene products that may be involved in reprogramming. In
contrast, in the transcription factor-mediated reprogramming method, the factors that initiate
the process are known and can be easily modulated which makes examination of the process
less complicated and easier to follow. However, the process is long, inefficient and
generates induced pluripotent stem cells (iPSCs) that vary widely in their developmental
potential1,2,9,10.
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In this review, we focus on recent studies and technologies aimed at understanding the
molecular mechanisms of cellular reprogramming mediated by transcription factors. For
example, insights have been gained from methods to study single cells as well as studies of
populations of cells undergoing reprogramming. We describe current views of the phases of
transcriptional and epigenetic changes that occur and discuss new concepts regarding the
role of OSKM in driving the conversion to pluripotency. We then consider markers of cells
progressing through reprogramming and emerging models of the process. Finally, we
summarize criteria that allow assessment of iPSC quality.
Phases of reprogramming
Insights gained from population-based studies
After the first demonstration of reprogramming to pluripotency by defined factors11,12,
many groups raced to study the reprogramming process by analyzing transcriptional and
epigenetic changes in cell populations at different time points after factor induction. These
are the most straightforward experiments to perform for unraveling the molecular
mechanism of this complicated process. Most studies analyzing cellular changes during the
reprogramming process were performed using populations of mouse embryonic fibroblasts
(MEFs).
Microarray data at defined time points during the reprogramming process13 showed that the
immediate response to OSKM is characterized by de-differentiation of MEFs and
upregulation of proliferation genes, consistent with the expression of c-Myc. Gene
expression profiling and RNAi screening in fibroblasts revealed three phases of
reprogramming termed initiation, maturation, and stabilization; the initiation phase marked
by a mesenchymal-to-epithelial transition (MET)14,15. Also, BMP signaling has been shown
to synergize with OSKM to stimulate a microRNA expression signature associated with
MET-promoting progression through the initiation phase15.
The late maturation and stabilization phases have been studied by tracing clonally-derived
cells16. This study showed that repression of the OSKM transgenes is required for the
transition from maturation to the stabilization phase. By comparing the expression profiles
of clones that could transit from the maturation to stabilization phase to those that could not,
the authors found a unique signature associated with competency. Surprisingly, few
pluripotency regulators played a role in the maturation-to-stabilization transition. Rather,
genes that are associated with gonads, gametes, cytoskeletal dynamics and signaling
pathway were upregulated during this phase16 (Figure 1). The authors also found that genes
that are induced upon transgene inhibition (for example, Eras and Lefty2) tend to be
important for ESC maintenance, whereas genes that retain a similar expression level before
and after transgene silencing (for example, Arid3b and Sall1) tend to be involved in
regulating the maturation-stabilization transition. This study suggests that the transition to
the stabilization phase upon transgene removal is dependent on regulatory pathways distinct
from those controlling ESC pluripotency16.
Another study used genome-wide analyses to examine intermediate cell populations poised
to become iPSCs17. This study revealed two distinct waves of major gene activity: the first
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wave occurred between days 0 and 3; and the second wave started after day 9, which is
toward the end of the process (day 12). The number of differentially expressed genes
between progressing cells and cells that are refractory to reprogramming at each time point
was gradually increased, reaching 1,500 genes by the end of the process17. The first wave
was characterized by the activation of genes responsible for proliferation, metabolism,
cytoskeleton organization, and downregulation of genes associated with development
(Figure 1). This step occurred in the majority of cells and is equivalent to the initiation phase
described above. Several early pluripotency-associated genes were upregulated gradually
and some developmental and cell-type-specific genes were transiently regulated during the
process. The second wave was characterized by the expression of genes responsible for
embryonic development and stem cell maintenance. Genes from this step facilitate the
activation of the core pluripotency network and mark the acquisition of a stable pluripotent
state. In contrast, genes related to extracellular space or matrix, plasma membrane, retinoic
acid binding, and immune response processes were aberrantly expressed in cells refractory
to reprogramming17.
In agreement with these findings, quantitative proteomic analysis during the course of
reprogramming of fibroblasts to iPSCs revealed a two-step resetting of the proteome during
the first 3 days and last 3 days of reprogramming18. Proteins related to regulation of gene
expression, RNA processing, chromatin organization, mitochondria, metabolism, cell cycle
and DNA repair were strongly induced at an early stage and proteins related to the electron
transport system were downregulated. In contrast to these processes, glycolytic enzymes
exhibited slow increase in the intermediate phase, suggesting a gradual transformation of
energy metabolism19. Proteins involved in vesicle-mediated transport, extracellular matrix,
cell adhesion and EMT were downregulated in the early phase, retained low levels during
the intermediate step and became up regulated in the final stage18. These data suggest that
reprogramming is a multi-step process characterized by two waves of transcriptome and
proteome resetting20.
Insights gained from single-cell studies
Knowledge gained from population-based studies is essential for the understanding of the
global changes that occur in cells during the reprogramming process. A challenge for
gaining mechanistic insights of reprogramming by the analysis of cell populations is cell
heterogeneity. Because only a small fraction of the induced cells become reprogrammed,
gene expression profiles of cell populations at different time points after factor induction
will not detect changes in rare cells destined to become iPSCs. In an attempt to overcome
the problem of cell heterogeneity, reprogramming has been traced at single-cell resolution
using time-lapse microscopy21,22. Single-cell tracking by real time microscopy has given
insights into morphological changes during reprogramming but the approach has not
provided information on molecular events driving the process at the single-cell level. These
studies showed that the cells underwent a shift in their proliferation rate and reduction in cell
size soon after factor induction. These events occurred within the first cell division and with
the same kinetics in all cells that give rise to iPSCs.
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As a complementary approach to the population-based studies, two single-cell techniques
have been utilized to quantify gene expression in the rare cells that undergo
reprogramming23: Fluidigm BioMark, which allows quantitative analysis of 48 genes in
duplicate in 96 single cells 24–27; and single-molecule-mRNA fluorescent in situ
hybridization (sm-mRNA-FISH), which enables the quantification of mRNA transcripts of
up to three genes in hundreds to thousands of cells28. The 48 genes in the BioMark system
included those known to be involved in major events that occur during reprogramming (for
example, proliferation, epigenetic modification, ESC supporting pathways, pluripotency
markers and MEF markers). In the first six days after factor induction, there was high
variation amongst cells in expression of the 48 genes23. This suggests that early in the
reprogramming process OSKM induce stochastic gene expression changes in a subset of
pluripotency genes, which are critical for instigation of the second phase (Figure 1). These
stochastic changes are in addition to the alterations in expression of genes that control MET,
proliferation and metabolism, which are global changes that must occur during
reprogramming but are not restricted to cells that are destined to become iPSCs15–17. Single-
cell analyses of clonally derived cell populations revealed that the stochastic gene
expression phase is long and variable23. Although cells with an ESC-like morphology
appear early, they must pass through a bottleneck - likely a rate-limiting stochastic event -
before transiting into stable iPSCs23,29. At a later stage, when the cells start to express
Nanog, the variation between individual cells decreases dramatically, consistent with a
model in which the early stochastic phase of gene expression is followed by a deterministic
or more “hierarchical” phase leading to activation of the pluripotency circuitry. This
deterministic or hierarchical phase is discussed further below in the context of models of
reprogramming.
Epigenetic changes
The studies discussed above characterized phases of transcriptional changes during
reprogramming, so what are the epigenetic alterations that underlie these changes and what
might drive them? The epigenetic signature of the somatic cell must be erased during the
conversion in order to adopt a stem cell-like epigenome. These changes include chromatin
reorganization, DNA demethylation of promoter regions of pluripotency genes like Nanog,
Sox2 and Oct4, reactivation of the somatically silenced X chromosome, and genome-wide
resetting of histone posttranslational modifications11,30–32. There are more than 100
different histone posttranslational modifications, with lysine methylation and acetylation
being the ones studied most frequently33. Changes in histone marks and the role of various
chromatin modifiers during reprogramming have been extensively reviewed
elsewhere4,34,35, so here we briefly summarize the key points. The roles of the relevant
histone marks and of chromatin modifiers are summarized in table 1 and table 2,
respectively.
DNA demethylation and X reactivation occur late in the reprogramming process17, whereas
changes in histone modifications can be seen immediately after factor induction36,
suggesting that changes in histone marks are an early event that is associated with initiation
of the reprogramming process. Immediately after factor induction, a peak of de novo
deposition of H3K4me2 is observed at promoter and enhancer regions. At this time,
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H3K4me2 accumulates at the promoters of many pluripotency genes, such as Sall4 and
Fgf4, which are enriched for Oct4 and Sox2 binding sites and lack H3K4me1 or H3K4me3
marks36. This stage is also associated with a gradual depletion of H3K27me3 and promoter
hypomethylation in regions that are important for the conversion17. However, at early time
points, H3K4me2 does not correlate with the transcription-associated histone mark
H3K36me3, occupancy of RNA PolII, or transcriptional activity suggesting that these loci
have not completed chromatin remodeling at early time points and an additional step is
required to achieve full activation of these genes36. At the beginning of the reprogramming
process, changes in these modifications are restricted almost exclusively to CpG islands, as
these regions are more responsive to transcription factor activity and permissive to
changes37. In parallel, the promoters of somatic genes begin to lose H3K4me2, consistent
with early down-regulation of MEF markers such as Thy1 and Postn38,39. A large number of
somatic gene enhancers also lose H3K4me2; this change leads to hypermethylation and
silencing at later stages. Thus, epigenetic modifications of key MEF-identity factors and
early pluripotency genes resulting in changes in their expression may represent one of the
first steps in the conversion of somatic cells to a pluripotent state.
Chromatin modifiers involved in reprogramming
Although histone marks are robustly modified during reprogramming, it is not clear which
chromatin modifiers participate in reshaping the epigenomic landscape of the somatic cells
and how they are targeted to genes whose altered expression is crucial for the conversion. It
is reasonable to assume that OSKM binding sites throughout the genome mark regions that
will be eventually epigenetically modified. Consistent with this notion is the finding that
Oct4 interacts with the WD-repeat protein-5 (Wdr5), a core member of the mammalian
Trithorax (trxG) complex, on pluripotency gene promoters and this maintains global and
localized H3K4me3 distribution40. The H3K27 demethylase enzyme Utx physically
interacts with OSK (Oct4, Sox2, Klf4) to remove the repressive mark H3K27me3 from early
activated pluripotency genes such as Fgf4, Sall4, Sall1 and Utf141. Loss of Utx is associated
with aberrant H3K27me3 distribution throughout the genome and with inhibition of
reprogramming41. Tet1 and Tet2, two methylcytosine hydroxylase family members that are
important for the early generation of 5-hydroxymethylcytosine (5hmC) during
reprogramming, can be recruited by Nanog to enhance the expression of a subset of key
reprogramming target genes such as Nanog itself, Esrrb and Oct4. Tet1 and Tet2 thus
appear to be involved in the demethylation and reactivation of genes and regulatory regions
that are important for pluripotency42–44. The poly (ADP-ribose) polymerase-1 (Parp1) has a
complementary role in the establishment of early epigenetic marks during somatic cell
reprogramming by regulating 5-methylcytosine (5mC) modification43. Brg1 and Baf155,
two components of the BAF chromatin remodelling complex, enhance reprogramming by
establishing a euchromatic chromatin state and enhancing binding of reprogramming factors
to key reprogramming gene promoters45. Overexpression of Brg1 and Baf155 induces
OSKM-mediated demethylation of pluripotency genes such as Oct4, Nanog and Rex1 and
enhances conversion to iPSCs.
Many other chromatin modifiers have been shown to play a role in resetting the epigenome
of reprogrammable cells (summarized in table 2). For example, Kdm2a and Kdm2b, which
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are H3K36me2 demethylases, cooperate with Oct4 and play a role in facilitating the
reprogramming process by regulating H3K36me2 levels at the promoters of early-activated
genes: mainly epithelial-associated genes, the microRNA 302/367 cluster and early
pluripotency genes46,47. In the conversion of human fibroblasts to iPSCs, the H3K9
methyltransferases EHMT1 and SETDB1, and five components of the Polycomb repressive
complexes (PRC) (BMI1, RING1 from PRC1, and EZH2, EED and SUZ12 from PRC2), are
required to reset the epigenome of the somatic cells; loss of these genes significantly reduces
iPSC formation48.
Another H3K9 methyltransferase, SUV39H, which contributes to heterochromatin
formation49, hinders the reprogramming process. This suggests that loss of SUV39H may
have a global effect on chromatin organization that leads to aberrant transcriptional
regulation or that H3K9 methyltransferases have different specificities, with some targeting
somatic state-associated genes and others targeting pluripotency-associated genes. Similarly,
the histone H3 lysine 79 (H3K79me2) methyltransferase DOT1L inhibits the
reprogramming process in the early to middle phase. Loss of DOT1L increases
reprogramming efficiency by facilitating loss of H3K79me2 from fibroblast-associated
genes such as the mesenchymal master regulators, SNAI1, SNAI2, ZEB1, and TGFB2.
Silencing of these genes is essential for proper reprogramming and indirectly increases the
expression of the pluripotency genes NANOG and LIN2848.
It will be interesting to explore whether specific combinations of chromatin modifiers are
able to reset the epigenome of a somatic cell and to reprogram it to pluripotency in the
absence of pluripotency factors. In addition, these data raise the question whether the four
factors themselves act as pioneer factors that direct conversion by physical interaction with
epigenetic and transcriptional regulators.
Roles of the OSKM factors
OSK as pioneer factors
Little is known about how ectopic expression of OSKM drives the conversion of somatic
cells to the pluripotent state. It has been shown that the first transcriptional wave is mostly
mediated by c-Myc and occurs in all cells whereas the second wave is more restricted to
reprogrammable cells and involves a gradual increase in the expression of Oct4 and Sox2
targets, leading to the activation of other pluripotency genes that aid in the activation of the
pluripotency network. Klf4 seems to support both phases by repressing somatic genes during
the first phase and facilitating the expression of pluripotency genes in the second phase17.
In mouse or human fibroblasts, immediately after factor induction, OSKM occupy
accessible chromatin, binding promoters of genes that are active or repressed34,36,38,50. In
addition, OSK proteins become associated with distal elements of many genes throughout
the genome that display minimal, if any, preexisting histone modifications or DNase I
hypersensitivity (Figure 2)50. Thus, the multiple distal genomic sites initially occupied by
OSK do not correspond to the distal genomic regions that are bound by these pluripotency
factors in ESCs; we will refer to this atypical binding of ectopic OSK in somatic cells as
“promiscuous binding” throughout the manuscript. Based on these observations it has been
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suggested that OSK may act as “pioneer” factors that open chromatin regions and allow the
activation of those genes that are essential for establishment and maintenance of the
pluripotent state50, whereas c-Myc only facilitates this process (the mode of action by which
c-Myc aids in the conversion is discussed extensively in the next section).
The initial promiscuous binding of OSKM, when expressed in fibroblasts, to target
sequences present in many genomic regions raises the question of their molecular role in the
conversion of somatic cells to pluripotent cells. Vector transduction-mediated or
doxycycline-induced expression of the reprogramming factors in fibroblasts probably does
not mimic the expression mode of the endogenous genes in ESCs, in terms of expression
levels and factor stoichiometry. This may result in the widespread and seemingly
promiscuous binding of OSKM to multiple regions in the genome, many of which are not
occupied by these factors in ESCs. Possibly, OSKM can interact with the Mediator or
Cohesin complexes or with RNA pol II elongation factor Ell3 and recruit them initially to
atypical distal enhancers to aid in the opening of these “closed” regions51,52. Mediator
bridges interactions between transcription factors at enhancers and the transcription
initiation apparatus at core promoters and in combination with RNA polymerase II and
TATA-binding protein (TBP) may gradually initiate transcription from those “blocked”
regions51. Binding of the “pioneer” factors OSK to “super enhancers” and the recruitment of
the Mediator complex may provide cell type specificity53 at later stages in the
reprogramming process. Supporting the notion that OSKM are capable of “loosening”
chromatin and inducing cell plasticity early in reprogramming is the observation that
transient expression of the factors is sufficient to open the chromatin and to induce
transdifferentiation of fibroblasts to other somatic cells, such as cardiomyocytes and neural
progenitor cells54,55.
Though the four factors often bind jointly to their targets, subsets and different combinations
of the factors frequently occupy non-overlapping genomic regions. For example, Klf4 and c-
Myc frequently bind jointly to promoters, whereas all the other OSKM combinations
predominantly occupy distal elements, at sites conserved between human and mouse50.
OSKM bind together at gene regions that initiate and support the conversion to pluripotency,
such as Glis1, mir-302/367 cluster, Fbxo15, Fgf4, Sall4 and Lin28, and factors that promote
mesenchymal to epithelial transition (MET)14,23,50,56–59. However, only half of the
enhancers that acquire H3K4me2 in the induced cells are shared enhancers with ESCs36
with the other half representing enhancers that are not ESC-specific, supporting the
promiscuous binding of OSKM to various genomic regions that aid in the conversation
process (Figure 2). Also, in addition to the four factors, activation of other genes early in the
reprogramming process may affect the efficiency and specificity of OSKM binding. Binding
of the “pioneer” factors OSK in combination with c-Myc to enhancer regions that are not
ESC-specific results in ectopic gene expression. This may render the initial cells susceptible
to other gene expression changes, such as activation of apoptotic genes, metabolic genes and
MET-inducing genes, silencing of MEF specific genes and eventually activation of
pluripotency genes17 (Figure 2).
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Revisiting the function of c-Myc in reprogramming
Because c-Myc enhances the transcription of proliferation-associated genes60–62, its role in
cellular reprogramming was initially attributed to its ability to promote proliferation and to
activate a set of pluripotency genes and microRNAs. C-Myc is a basic helix loop helix
(bHLH) transcription factor that at basal levels interacts with Max on actively transcribed
genes via E-box sequences63. It has been shown to be dispensable for reprogramming but
facilitates the emergence of rare reprogrammed cells64,65. Supporting this observation is the
finding that c-Myc does not greatly contribute to the activation of pluripotency regulators in
partially reprogrammed cells and that its expression is essential only for the first five days38.
However, in ESCs, c-Myc augments the transcription elongation of many actively
transcribed genes via their core promoter regions and by these means maintains
pluripotency66.
Recently, the role of c-Myc during transcription has been revisited, and it has been
demonstrated that c-Myc does not regulate a unique set of target genes but rather acts as a
general amplifier of gene expression, increasing the transcription at all active
promoters67,68. In contrast to many other transcription factors that activate genes in a binary
switch way69, c-Myc binding resembles a continuous, analog process67: c-Myc binding to
promoter regions is associated with open chromatin marks including H3K4me3 and
H3K27ac and is correlated with the amount of RNA polymerase recruited at those
promoters67,68. C-Myc recruits the pause release factor P-TEFb, increases transcriptional
elongation and the transcription levels66,70,71 and when overexpressed, its localization to the
enhancers of active genes is increased substantially through binding to a variant E-box
motif. When OSK are overexpressed together with c-Myc, OSK act as pioneer factors to
enable c-Myc to bind to regions that are in inaccessible chromatin. In parallel, driven in part
by a variant c-Myc binding site50, c-Myc also cooperatively enhances the initial OSK
engagement with chromatin. Continuous binding of the factors to those “blocked” distal
elements leads to binding at the promoters of genes that acquire a de novo H3K4me2, and
eventually leads to the transcription of those genes.
It will be interesting to examine whether in cancer cells other pioneer factors recruit c-Myc
to specific “blocked” regions through the variant E-box motif. Given this notion, c-Myc
expression should enhance any given transdifferentiation or cellular reprogramming process.
However, expression of c-Myc in combination with transcription factors that generate iPSCs
but lack Oct4 (such as Sall4, Nanog, Esrrb and Lin28) only slightly enhanced the
reprogramming process23, suggesting that different key factors have a different affinity for
c-Myc. Future studies should address how different key factors cooperate with this master
transcriptional amplifier.
Factor stoichiometry
The number of proviruses in iPSCs differs widely among the factors, suggesting that
reprogramming requires different expression levels of the individual factors23,31. Indeed,
factor stoichiometry can profoundly influence the epigenetic and biological properties of
iPSCs, as was demonstrated by comparing two genetically characterized doxycycline-
inducible transgenic ”reprogrammable” mouse strains72,73. The authors showed that,
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although a high number of iPSC colonies could be obtained, about 95% exhibited aberrant
methylation of the Dlk1-Dio3 locus and were unable to generate mice derived entirely from
iPSCs (“all-iPSC” mice) by tetraploid complementation, which is the most stringent test for
pluripotency73. In contrast, another study using an almost identical “reprogrammable”
transgenic donor mouse strain showed that the majority of iPSCs had retained normal
imprinting at the Dlk1-Dio3 locus and were competent to generate “all-iPSC” mice by
tetraploid complementation72. The only difference between the two transgenic systems was
a different stoichiometry of the reprogramming factors: high quality iPSCs resulted from the
donor strain that generated 10 to 20 fold higher levels of Oct4 and Klf4 protein and lower
levels of Sox2 and c-Myc72 than the donor strain that produced low quality iPSCs73.
Consistent with this notion, two other studies concluded that high levels of Oct4 and low
levels of Sox2 are preferable for iPSC generation74,75.
The levels of transgene expression also play a role in the formation of partially
reprogrammed iPSCs. It has been shown that partially reprogrammed colonies express a
unique set of genes that are often bound by more reprogramming factors in the intermediate
state than in ESCs38 (for example, promoter or enhancer regions that are bound only by
Oct4 and Sox2 in ESCs are bound by OSKM in the intermediate stage). In contrast, genes
that are highly expressed in ESCs are bound by fewer reprogramming factors in the partially
reprogrammed cells. Promoter regions bound by OSKM in partially reprogrammed cells
often contain known DNA binding sites for the bound factors, indicating that the factors
might bind those sites when the factors are present at high levels. These observations are
consistent with the notion that excess levels of transgenes or different factor stoichiometry
can cause binding of the four factors in a manner that differs from that seen in ESCs.
Therefore, the promiscuous binding of OSKM may be influenced by the stoichiometry of
the four factors and can either facilitate or block reprogramming.
Other parameters known to affect the characteristics of pluripotent cells are the culture
conditions and supplements used to derive the cells76. For example, addition of small
molecules and supplements such as vitamin C, valproic acid (VPA) and Tgf-β inhibitors to
the medium lead to more efficient derivation of iPSCs77–80. More importantly, derivation of
iPSCs in the absence of serum and in the presence of vitamin C produced high quality
tetraploid complementation-competent iPSCs even when a suboptimal factor stoichiometry
was used for inducing pluripotency81,82. In addition, use of physiological oxygen levels
during the isolation of human ESCs (hESCs) led to hESCs with two active X chromosomes,
whereas X inactivation occurs if conventional conditions are used83. Thus, the available
evidence suggests that factor stoichiometry as well as specific culture conditions strongly
affect the quality and the efficiency of iPSC generation (summarized in Table 3).
Markers of reprogramming
Ectopic expression of the reprogramming factors induces a heterogeneous population of
cells with individual cells embarking on different fates such as cell death, cell cycle arrest
(senescence), uncontrolled proliferation (malignant transformation), transdifferentiation and
partial or full reprogramming (Figure 1). Although it is easy to differentiate between non-
reprogrammed and reprogrammed cells, it is more challenging to distinguish partially from
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fully reprogrammed cells. This is because partially reprogrammed cells can be
morphologically identical to ESCs and can express many pluripotency genes23. Also, due to
the stochastic nature of reprogramming29, no molecular markers have been identified that
would predict whether a given cell early in the process will generate an iPSC daughter.
Changes including loss of MEF markers, activation of the MET program or appearance of
markers such as stage-specific embryonic antigen 1 (SSEA1) or alkaline phosphatase (AP)
must occur in the reprogramming process, but these are not restricted to cells destined to
become iPSCs23,18,59.
To define molecularly the various phases of the reprogramming process, global gene
expression and proteomic patterns of clonal cell populations or enriched populations were
established at different stages after factor induction15–18. These analyses suggested genes
such as Fbxo15, Fgf4, Sall1, Fut9, Chd7, Cdh1 mark the initiation phase, genes including
Sall4, Oct4, Nanog, Eras, Nodal, Sox2 and Esrrb are activated during the intermediate or
maturation phase, and genes such as Zfp42, Gdf3, Dppa2, Dppa3 and Utf1 might define the
late or stabilization phase. However, the information from gene expression or proteomic
analyses of heterogeneous populations is limited because the rare cells destined to become
iPSCs are masked.
Single-cell expression analyses of intermediate SSEA1-positive cells identified early,
intermediate and late makers, These included the early epithelial cell adhesion molecule
(EPCAM), the intermediate c-Kit receptor and the late platelet endothelial cell adhesion
molecule (PECAM1)17. Sorting SSEA1-positive, EpCAM-positive early cells showed
modest increase in reprogramming efficiency, but could not predict which cells would
eventually reprogram17. Pluripotency genes such as Utf1, Esrrb, Lin28 and Dppa2 were
identified as potential “predictive” indicators that were activated in a small subset of cells
and might mark cells early in the process that are destined to become iPSCs23. Some of
these markers were also detected in the population-based studies but, in contrast to single
cell analyses, were only detected at late stages of the process and thus could not identify
potential genes whose activation may constitute early markers for cells destined to become
iPSCs. The question whether these genes execute a crucial role in the conversion to fully
reprogrammed cells or only mark those rare cells is unresolved.
Endogenous copies of the key reprogramming factors Oct4 and Sall4 are activated early in
rare cells but are also activated in partially reprogrammed cells and thus do not represent
“predictive” early markers for iPSC generation23; this was confirmed in a study using an
inducible Oct4 lineage label84. In agreement with these observations, Sall4 and endogenous
Oct4 have been found to be poor predictors of reprogramming competency16.
Models of reprogramming
Somatic stem cells vs. differentiated donor cells
Because the generation of cloned animals by SCNT is so inefficient, it was hypothesized
that cloned animals like Dolly the sheep may not have been derived from differentiated cells
as assumed but rather from rare somatic stem cells present in the heterogeneous donor cell
population85. This issue was resolved when mature B and T cells were used as donors to
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create monoclonal mice that carried in all tissues the immunoglobulin and T cell receptor
rearrangements of the B and T cell donors, respectively, thus proving a terminally
differentiated donor cell86. Similarly, because reprogramming by transcription factors is
inefficient, it appeared possible that only a fraction of cells are able to generate iPSCs,
consistent with an “elite model” in which only rare somatic stem cells present in the donor
population could generate iPSCs whereas the differentiated cells would be refractory to
reprogramming87,88. Several lines of evidence rule out the elite model and argue that all
cells, including terminally differentiated cells, have the potential to generate iPSC daughters.
Firstly, iPSC colonies have been derived from terminally differentiated cells such as B cells,
T cells, liver and spleen cells82,89–91. As with SCNT, specific genomic rearrangement of the
immunoglobulin locus or the T cell receptor in iPSC clones proved unambiguously that the
cells were indeed derived from mature B or T cells and excluded the possibility of
mesenchymal stem cell contamination90. Secondly, clonal analysis of single B cells
indicated that >90% have the potential to generate daughter cells that at some point become
iPSCs29.
The stochastic and deterministic modes of reprogramming
In principle, reprogramming of somatic cells could occur by two mechanisms: a “stochastic”
mode in which iPSCs appear with variable latencies; or a “deterministic” mode in which
reprogrammed cells would be generated with a fixed latency. In the stochastic model it
cannot be predicted whether or when a given cell would generate an iPSC daughter. Strong
support for the stochastic model comes from single-cell cloning experiments demonstrating
that sister cells from an early colony generate iPSCs with variable latency and with some
sister cells never giving rise to iPSCs23,92. Though it cannot be predicted whether or when a
given cell will generate an iPS daughter cell, activation of some genes such as Esrrb or Utf1
(as discussed above), may mark rare early cells that are on their path to iPSCs (Figure 3).
Activation of these genes early in the process suggests that their promoter regions are
accessible for OSKM (Figure 2)15–17,23. In contrast, late activated loci are marked by
H3K9me3 and are refractory to OSKM binding at early stages and activation of these loci
appears to be a critical step for the proposed transition from a stochastic to a deterministic
phase (Figure 1 and 3;50,93). Indeed, several essential pluripotency loci that are marked by
H3K9me3, such as Nanog, Dppa4, Gdf3 and Sox2, are activated later in reprogramming and
are refractory to activation by the reprogramming factors during early stages13,15,16,23,38,50
(Figure 1 and 2). Thus, the removal of H3K9me3 may represent another primary epigenetic
barrier to complete reprogramming93.
The key event initiating the late hierarchical phase appears to involve activation of the
endogenous Sox2 gene, which then triggers a series of steps of gene activation that allow the
cells to enter the pluripotent state23 (Figure 1 and 3). Sox2 represents one of a group of
pluripotency initiating factors (PIFs) that are crucial and indispensable for the instigation of
the deterministic phase16,23. The hierarchical network displayed in Figure 1 predicts that
factors other than the canonical Yamanaka factors Oct4, Sox2, Klf4, c-Myc or Nanog should
be able to induce pluripotency. Indeed, down-stream factors such as Esrrb, Lin28, Dppa2
and Sall4 were sufficient to induce iPSCs from MEFs23.
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It has been suggested that the initial response to ectopic expression of OSKM in somatic
cells may be an orchestrated and possibly deterministic response involving epigenetically
definable events that activate loci critical for pluripotency17,22. Here we suggest an
alternative view of the initial interaction of OSKM with the genome. As outlined in Figure
3, initial stochastic gene activation may render the cells susceptible to other gene expression
changes (such as activation of apoptotic genes, metabolic genes, MET-inducing genes,
silencing of MEF specific genes and eventually activation of pluripotency genes)17. During
this initial phase, stochastic OSKM-genome interactions could also instigate the activation
of early PIFs such as Esrrb or Utf123 in rare cells (Figure 3), and these would eventually
lead to the expression of the late pluripotency genes Sox2 and Nanog and stabilization of the
core pluripotency circuitry. At this later stage, the endogenous pluripotency factors (Oct4,
Sox2 and Nanog (OSN)) will, in contrast to the exogenous OSKM factors, occupy only
ESC-specific target regions94.
The initial promiscuous interaction of OSKM with the genome might be initiated by any
factor that destabilizes the compacted chromatin typical of somatic cells. It is this
destabilization that may render the somatic chromatin susceptible to becoming
“hyperdynamic”, which is the hallmark of the ESC epigenetic state95,96. Consistent with this
notion are the findings that general chromatin remodeling complexes such as BAF45,97, or
global basal transcription machinery components like the transcription factor IID (TFIID)
complex98, or exposure of cells to general DNA methyltransferase and histone deacetylase
inhibitors like 5-azacytidine13 and valporic acid78, can substantially enhance reprogramming
in cooperation with OSKM. Also, in fibroblasts, down-regulation of the global chromatin
organization modulator Lamin A, which is not expressed in ESCs99, has been reported to
increase reprogramming efficiency100. Thus, although OSKM are highly efficient in
inducing pluripotency, any chromatin remodeler or transcription factor - even those that do
not normally function in ESCs - might be able to initiate the process leading to pluripotency,
albeit with an efficiency that might be too low to be detected in standard reprogramming
assays.
It has been suggested that reprogramming by SCNT or by somatic cell-ESC fusion is
deterministic as it leads to activation of the somatic Oct4 within two cell divisions (in the
case of SCNT) or in the absence of DNA replication (in the case of fusion)1,2. However, to
define pluripotency functionally in cloned embryos or in heterokaryons has been difficult, so
it remains to be determined whether these methods activate the pluripotency circuitry by
deterministic or stochastic mechanisms. Both types of mechanism might be involved in the
various forms of reprogramming.
How similar are ES and iPS cells?
Although ESCs and iPSCs are similar in morphology, age-affected cellular systems such as
telomeres and mitochondria101,102, surface markers and overall gene expression, a number
of studies have identified biological and epigenetic differences between ESCs and iPSCs as
well as among individual ESC and iPSC lines103–115. For example, genetic alterations and
differences in the transcriptome, proteome and epigenome were detected when ESCs and
iPSCs were compared; these have raised concerns about the safety of iPSCs for therapeutic
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applications. However, other studies have failed to find epigenetic and genetic abnormalities
that consistently distinguish iPSCs from ESCs105,116–119. Rather, these data suggested that
the extent of variations seen between ESCs and iPSCs were similar to variations seen within
different ESC lines or within different iPSC lines120.
Recently, it has been suggested that the genetic abnormalities seen in iPSCs might be a
result of oncogenic stress induced by the four reprogramming factors121. Significantly
higher level of phosphorylated histone H2AX, one of the earliest cellular responses to
double-strand breaks (DSBs) DNA, was detected in cells exposed to OSKM or OSK. The
authors also linked the homologous recombination pathway, a pathway essential for error-
free repair of DNA DSBs, to the reprogramming process and suggested a direct role for this
pathway in maintaining genomic integrity121. In summary, the available evidence has not
settled whether the alterations seen in iPSCs are the result of the reprogramming process per
se or due to pre-existing genetic and epigenetic differences within individual parental
fibroblasts119,122.
Much evidence indicates that the biological properties, such as in vitro differentiation, differ
among individual ESC and iPSC lines, raising the concern that the unpredictable variation
among cell lines could pose a potentially serious problem for iPS-based disease research.
That is, a subtle phenotype seen between a disease-specific iPSC and a control iPSC line
might not be relevant to the disease but rather reflect a system immanent difference123.
Efforts have been directed towards defining experimental conditions of iPSC and ESC
derivation that affect the developmental potential of the cells (summarized in Table 3).
Perspective
The 2012 Nobel Prize in Physiology and Medicine was awarded to Shinya Yamanaka and
John Gurdon for their discoveries on reprogramming somatic cells to pluripotency124. The
seven years since Yamanaka's first demonstration of somatic reprogramming using defined
factors12 have witnessed much progress in understanding this complex process, and the most
straightforward experiments have been done. However, many questions pertaining to the
molecular mechanism of reprogramming remain unsolved. For example: how do OSKM
convert chromain to a “hyperdynamic” state; how does the promiscuous binding of OSKM
in somatic cells contributed to the reprogramming process; what defines the rate-limiting
step; what are the criteria for and the most effective methods for producing high quality
iPSCs? Addressing these questions will be essential for a deeper understanding of
reprogramming and will require the development of new technologies allowing genome
wide epigenetic analyses of individual cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Phases of the reprogramming process
In the model we discuss in this review, the reprogramming process can broadly be divided
into two phases: firstly, a long `stochastic' phase of gene activation; and secondly, a shorter
hierarchical more `deterministic' phase of gene activation that begins with the activation of
the Sox2 locus. After a fibroblast is induced with OSKM, it will initiate stochastic gene
expression and assume one of several possible fates (such as, apoptosis, senescence,
transformation, transdifferentiation or reprogramming). In the early phase, reprogrammable
cells will increase proliferation, undergo changes in histone modifications at somatic genes,
initiate mesenchymal to epithelial transition, and activate DNA repair and RNA processing.
Then the reprogrammable cells will enter an intermediate phase with an unknown rate-
limiting step that delays the conversion to iPSCs and contributes to the long latency of the
process. In this phase, cells undergo a stochastic activation of pluripotency markers23, a
transient activation of developmental regulators17, and activation of glycolysis18. In general
the transcriptional changes in this phase are small. In some rare cases, the stochastic gene
expression will lead to the activation of "predictive markers" such as Utf1, Esrrb, Dppa2,
and Lin28, which then will instigate the second phase that starts with the activation of Sox2.
Activation of Sox2 by the “predictive markers” can be direct or indirect and will trigger a
series of deterministic events that will lead to an iPSC. In this late phase, the cells eventually
stabilize into the pluripotent state in which the transgenes are silenced, the cytoskeleton is
remodeled to an ESC-like state, the epigenome is reset and the core pluripotency circuitry is
activated16–18,23. In this model, probabilistic events decrease and hierarchical events
increase as the cell progresses from a fibroblast to an iPSC.
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Figure 2. OSKM as pioneer factors for remodeling the epigenome
During reprogramming, exogenous OSKM bind enhancers and promoters of fibroblast and
ESC genes along with regions that are not occupied by OSKM in ESCs and are not specific
to fibroblasts (here called `somatic'). The factors mark the loci that eventually will be
epigenetically modified. In general, OSKM bind four different classes of genes. The first
class (Fib) contains genes that are important for the identity of the fibroblasts such as Thy1,
Postn, Col5a2 and EMT genes like SnaiI, SnaiII and Twist1. The second class (Somatic)
contains genes that are bound by OSKM in somatic cells but not in ESCs and are not
specific to fibroblasts. This includes apoptotic genes such as p53, genes that are important
for proliferative cells, such as cell cycle genes (for example Bub1, Cdc20 and Cdc25c), and
metabolic genes such as Pfkl and Gp. The third class (ES-I) contains ESC genes that are
activated early in the process such as Fbxo15, Fgf4 and Sall4. The fourth class (ES-II)
contains genes that are activated late in the reprogramming process such as Sox2, Nanog and
Dppa4. During the early phase of reprogramming, OSKM occupy the enhancers of all
classes except enhancers of ES-II genes that contain the heterochromatin mark H3K9me3
and are refractory to the four factors. c-Myc and Klf4 bind promoters of Fib genes and
repress their activity while increasing the activation of genes from the Somatic class (shown
by the weight of the arrow). As a result, enhancers and promoters from Fib start to lose
H3K4me2 while genes from the Somatic class maintain high levels of H3K4me2. OSK act
as pioneer factors and occupy the distal enhancer of ES-I genes, which gain de novo
H3K4me2 and will initiate expression a few days later. The late phase is less well
understood, but it can be speculated that Fib genes become heterochromatic and are silenced
while the genes from the Somatic class are highly activated. ES-I genes are highly activated
and contain high levels of H3K4me2 and ES-II genes start to lose the H3K9me3 mark, gain
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H3K4me2 marks and initiate expression. It is reasonable to assume that more pluripotency
late factors that are switched on late in reprogramming are needed to open those “blocked”
regions. After the silencing of the exogenous factors, all groups are highly expressed except
Fib, which remains silenced. The sizes of the ovals representing OSKM indicate their
binding preference. For example, c-Myc is a global amplifier of gene expression increasing
the transcription at all active promoters, therefore the oval “M” is larger on promoters.
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Figure 3. Model of molecular events that precede iPS formation
In the early phase, ectopic OSKM act as pioneer factors and occupy many genomic regions
and help to generate a hyperdynamic chromatin state. OSKM will bind many regions
throughout the genome of the fibroblast that are not OSKM targets in ESCs. Among these
regions are: genes that determine the identity of the fibroblast, like extracellular components
and EMT genes (orange box); genes that promote proliferation and increase metabolism (red
box); unknown target genes that facilitate genomic fluidity, i.e., a state that allows rapid
changes in transcription (gray box). In addition, OSKM will occupy distal regions of early
pluripotency genes (black box); this binding will aid in activating those loci at later stages.
A group of late pluripotency genes (blue box) is refractory to OSKM binding in this early
phase. In the early hierarchical phase (which is more speculative), early pluripotency genes
become activated in rare individual cells and either directly or in a hierarchical manner will
instigate a more deterministic process that eventually leads to the activation of Sox2. Sox2
represents one gene of a group of late pluripotency initiating factors (PIFs) that are essential
for the activation of the core pluripotency circuitry. Once activated, the endogenous
pluripotency proteins Oct4, Sox2 and Nanog (OSN) occupy their target genes94 and
maintain the iPSC state in the absence of the exogenous factors.
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Table 1
Roles of various histone marks during reprogramming
Histone mark Function Phase of
reprogramming in
which change occurs
Example of change
Histone H3 lysine 4
dimethylation (H3K4me2)
Marks promoters and enhancers Early phase Decrease at MEF and EMT genes.
Increase at proliferation,
metabolism, pluripotency and MET
genes34,36,38,50
Histone H3 lysine 4
trimethylation (H3K4me3)
Marks active loci Early phase Increase at proliferation and
metabolism genes34,36,38
Histone H3 lysine 27
trimethylation (H3K27me3)
Marks repressed loci Early phase Increase at MEF and EMT
genes34,36,38
Histone H3 lysine 4
monomethylation (H3K4mel)
Marks enhancers Early phase Increase at proliferation and
metabolism genes36
Histone H3 lysine 36
trimethylation (H3K36me3)
Marks transcriptionally active regions Early to Middle phase Increase at early and late
pluripotency genes36
Histone H3 lysine 9
trimethylation (H3K9me3)
Marks heterochromatin regions Late phase Decrease at late pluripotency
genes50,93
Histone H3 lysine 36
diimethylation (H3K36me2)
Marks potential regulatory regions
(such as newly transcribed genes)
Early phase Increase at early pluripotency
genes46,47
Histone H3 lysine 79
diimethylation (H3K79me2)
Marks transcriptionally active regions Early to middle phase Decrease at MEF and EMT genes48
Histone H3 lysine 27 acetylation
(H3K27ac)
Marks open chromatin and active
enhancers
Unknown Unknown
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Table 2
Roles of example chromatin modifiers in reprogramming
Chromatin modifier factor Enzymatic function Role in reprogramming
Utx H3K27 demethylase Physically interacts with OSK to remove the repressive
mark H3K27 from early pluripotency genes41
Kdm2a/2b H3K36 demethylases Initiation of the reprogramming process by regulating
H3K36me2 levels at the promoters of early-activated
genes46,47
Ehmt1, Setdb1 H3K9 methyltransferases Required to reset the epigenome of somatic cells48
Bmi1, Ring1, Ezh2, Eed, Suz12 H3K27 methyltransferases Involved in maintaining the transcriptional repressive state
of genes48
Suv39h H3K9 methyltransferase Contributes to heterochromatin formation, hinders the
reprogramming process48
Dotl1 H3K79 methyltransferase Inhibits the reprogramming process in the early to middle
phase by maintaining the expression of EMT genes such as
SNAI1, SNAI2, ZEB1, and TGFB248
Parp1 Chromatin-associated enzyme, poly(ADP-
ribosyl)transferase, which modifies various
nuclear proteins by poly(ADP-ribosyl)ation
Functions in the regulation of 5mC, targets Nanog and
Esrrb43
SWI/SNF (BAF) complex Chromatin remodeling complex Induce demethylation of pluripotency genes such as Oct4,
Nanog and Rex145
Tet1 and Tet2 Methylcytosine dioxygenase that catalyzes
the conversion of methylcytosine to 5-
hydroxymethylcytosine
Important for the early generation of 5hmc by oxidation of
5mC, targets Nanog, Esrrb and Oct4 through physical
interaction with Nanog42–44.
Wdr5 complex A core member of the mammalian
Trithorax (trxG) complex. An “effector” of
H3K4 methylation.
Interacts with Oct4 on pluripotency gene promoters and
facilitates their activation40.
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Table 3
Parameters that influence the quality of iPSCs
Parameter Reprogramming cocktail or conditions Effect on the quality of iPSCs
Stoichiometry High Oct4, high Klf4, low Sox2, low c-Myc Low reprogramming efficiency, normal Dlkl-Dio3 (A)
methylation, no tumors in mice, improved efficiency to
produce 4n mice72
High Sox2, high c-Myc, low Oct4, low Klf4 High reprogramming efficiency, aberrant methylation of Dlkl-
Dio3, tumors in mice, low efficiency to produce 4n mice73
Other factors Tbx3 (B), Zscan4 C Improve reprogramming efficiency and/or improved efficiency
to produce 4n mice125,126
Culture conditions Knockout DMEMD, 20% KSRE Efficient generation of iPSCs from MEFs and TTFs, improved
efficiency to produce 4n mice127
O2 levels Hypoxia conditions improve iPSC generation and aid X
reactivation83
Supplement Vitamin C Activates Dlkl-Dio3 locus, improved efficiency to produce 4n
mice82
Histone deacetylase inhibitor Activates Dlkl-Dio3 locus, improved efficiency to produce 4n
mice.73
2i/LIFF Upregulation of Oct4 and Nanog, competence for somatic andgermline chimerism128
Protein arginine methyltransferase inhibitor
AMI-5 and Tgf-βG inhibitor A-83-01
Improved efficiency to produce 4n mice129
Genetic and epigenetic
background
Not applicable Unknown
4n mice: mice produced through tetraploid complementation
A
Imprinted control domain that contains the paternally expressed imprinted genes DLK1, RTL1, and DIO3 and the maternally expressed imprinted
genes MEG3 (Gtl2), MEG8 (RIAN), and antisense RTL1 (asRTL1). Reported to distinguish “good” (those that generate all-iPSC mice and
contribute to chimeras) iPSCs from “bad” (those that do not generate all-iPSC mice and contribute to chimeras) iPSCs in Stadtfeld et al. Nature
2010. Carey et al. Cell Stem Cell 2011 found that loss of imprinting at the Dlkl-Dio3 locus did not strictly correlate with reduced pluripotency.
B
Tbx3 encodes a transcriptional repressor involved in developmental processes.
C
Zscan4 encodes a protein involved in telomere maintenance, specifically aiding cell in escaping senescence. Also plays a role as a pluripotency
factor.
D
Dulbecco's Modified Eagle Medium
E
KnockOut Serum Replacement
F
Leukemia Inhibitory Factor
G
Transforming Growth Factor Beta
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